odiparcil has been researched along with Disease Models, Animal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Bocart, S; Bouchot, A; Bournique, B; Broqua, P; Entchev, E; Jantzen, I; Junien, JL; Lacombe, O; Luccarini, JM; Masson, P; Tallandier, M | 1 |
| Antonelli, S; Cimbolini, N; Entchev, E; Feraille, L; Germain, JM; Jantzen, I; Lacombe, O; Luccarrini, JM; Mauro, V; Roussey, A; Tallandier, M; Young, SP; Zhang, H | 1 |
| Abboud, MA; Burns-Kurtis, CL; Danoff, TM; Erhardt, JA; Koster, PF; Pillarisetti, K; Toomey, JR; Valocik, RE | 1 |
4 other study(ies) available for odiparcil and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Topics: Administration, Oral; Animals; Cattle; Cells, Cultured; Chondroitin Sulfates; Dermatan Sulfate; Disease Models, Animal; Endothelial Cells; Female; Glycosaminoglycans; Glycosides; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mucopolysaccharidosis VI; Rats; Rats, Sprague-Dawley | 2020 |
MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
Topics: Animals; Disease Models, Animal; Eye; Eye Diseases; Glycosides; Humans; Mice; Mucopolysaccharidosis VI; N-Acetylgalactosamine-4-Sulfatase; Phenotype | 2022 |
A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.
Topics: Animals; Anticoagulants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycosaminoglycans; Glycosides; Hemorrhage; Heparin Cofactor II; Protamines; Rats; Vena Cava, Inferior; Venous Thrombosis; Warfarin | 2006 |